The WSJ suggests that a Japanese Pharmaceutical Company, Shionogi, has researched a new compound which prevents/inhibits host intercellular viral replication.
This is unique in terms of anti-viral action.
The drug is not named.
A placebo controlled, randomised, double blinded study showed efficacy against a range of coronaviruses over oseltamivir (a robust anti-viral) with fewer side effects.
Thus XOFLUZA is theoretically a potentially therapeutic treatment for COVID-19❗️
Obviously specific clinical trials have not been performed on COVID-19.
Indeed I have found an article where Chinese Physicians are considering just that❗️👇